Time Savings with Once-Monthly C.E.R.A.: A Time and Motion Study Conducted in 13 Haemodialysis Centres in Italy

Blood Purif. 2015;40(2):173-9. doi: 10.1159/000437133.

Abstract

Background: We sought to document the time required by health care professionals to administer erythropoiesis-stimulating agents (ESAs) and continuous erythropoiesis receptor activator (C.E.R.A.) in the management of renal anaemia.

Methods: A Time and Motion study was conducted in 13 centres in Italy. The time spent on preparation, distribution, and injection for both ESA and C.E.R.A. groups was measured. A multilevel model was run to account for the centre-clustering effect.

Results: The average number of ESA injections/patient/year was 89. The average uptake of C.E.R.A. was 26%. The average time per session was 1.54 min for ESA (95% CI 1.21-1.86) vs. 1.64 min for C.E.R.A. (95% CI 1.31-1.97). Estimated time/patient/year was 137 min for ESA and 20 min for C.E.R.A. Assuming a 100% uptake of C.E.R.A., annual time savings/centre would be 84% (194 h).

Conclusions: Substantial annual time savings on frequent anaemia management-related tasks were found when a switchover was made from ESAs to C.E.R.A.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia / pathology
  • Anemia / therapy*
  • Drug Administration Schedule
  • Erythropoiesis / drug effects
  • Erythropoietin / therapeutic use*
  • Hematinics / therapeutic use*
  • Humans
  • Italy
  • Kidney Failure, Chronic / economics
  • Kidney Failure, Chronic / pathology
  • Kidney Failure, Chronic / therapy*
  • Prospective Studies
  • Renal Dialysis / economics*
  • Renal Dialysis / methods
  • Time Factors
  • Time and Motion Studies*

Substances

  • Hematinics
  • Erythropoietin